{"id":"NCT04723394","sponsor":"AstraZeneca","briefTitle":"Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-28","primaryCompletion":"2021-08-21","completion":"2022-10-19","firstPosted":"2021-01-25","resultsPosted":"2022-12-20","lastUpdate":"2023-07-05"},"enrollment":910,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"AZD7442","otherNames":["Combination of 2 mAbs (AZD8895 and AZD1061)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AZD7442","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.","primaryOutcome":{"measure":"A Composite of Either Severe COVID-19 or Death From Any Cause Through Day 29","timeFrame":"Baseline (Day 1) and Day 29","effectByArm":[{"arm":"AZD7442","deltaMin":18,"sd":null},{"arm":"Placebo","deltaMin":37,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.010"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":103,"countries":["United States","Argentina","Brazil","Czechia","Germany","Hungary","Italy","Japan","Mexico","Peru","Poland","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["27578435","4023479","30252327","20337631","32539990","32015507","15033648","38403865","37751015","35688164","34473343"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8851C00001&amp;attachmentIdentifier=dd6cb212-7d2d-40c2-a4b9-39d661461486&amp;fileName=Clinical_Study_Protocol_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8851C00001&amp;attachmentIdentifier=7e4b7190-a3a8-49b7-8cce-8d5b0c3da7ae&amp;fileName=Statistical_Analysis_Plan__Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8851C00001&amp;attachmentIdentifier=a1495ac4-8d00-4c45-b026-1f0084417cb8&amp;fileName=CSR_Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":452},"commonTop":["COVID-19","Post-acute COVID-19 syndrome","Hypertension","Fatigue","Vaccination complication"]}}